{
    "clinical_study": {
        "@rank": "114195", 
        "arm_group": [
            {
                "arm_group_label": "Exposure in vivo", 
                "arm_group_type": "Experimental", 
                "description": "This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993)."
            }, 
            {
                "arm_group_label": "Virtual Reality Exposure Therapy", 
                "arm_group_type": "Experimental", 
                "description": "This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.\nThe difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
            }, 
            {
                "arm_group_label": "Wait-list", 
                "arm_group_type": "No Intervention", 
                "description": "Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The current study aims at comparing the efficacy of exposure in vivo and exposure via\n      virtual reality for social anxiety disorder. 70 patients with social anxiety disorder will\n      be randomized to either one of the active conditions or to a waiting-list condition.\n      Participants on the waiting-list will be offered either exposure in vivo of in virtual\n      reality after a waiting period of five weeks. Levels of psychopathology will be assessed at\n      pre- and post-treatment as well as three and 12 months after treatment."
        }, 
        "brief_title": "Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Social Anxiety Disorder", 
            "Social Phobia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Phobic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 65 years old\n\n          -  a primary diagnosis of social anxiety disorder as measured with the SCID\n\n          -  fluency in Dutch.\n\n        Exclusion Criteria:\n\n          -  psychotic episodes in the past, suicidal intentions or substance dependence.\n\n          -  behavior therapy in the preceding one year."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746667", 
            "org_study_id": "05510207"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exposure in vivo", 
                "intervention_name": "Exposure in vivo", 
                "intervention_type": "Behavioral", 
                "other_name": "Behavior Therapy"
            }, 
            {
                "arm_group_label": "Virtual Reality Exposure Therapy", 
                "intervention_name": "Virtual Reality Exposure Therapy", 
                "intervention_type": "Behavioral", 
                "other_name": "Virtual Reality Therapy"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Social Anxiety Disorder", 
            "Social Phobia", 
            "Virtual Reality", 
            "Exposure"
        ], 
        "lastchanged_date": "December 8, 2012", 
        "location": {
            "contact": {
                "email": "I.L.Kampmann@uva.nl", 
                "last_name": "Isabel L Kampmann, MSc", 
                "phone": "0031-205257084"
            }, 
            "contact_backup": {
                "email": "n.morina@uva.nl", 
                "last_name": "Nexhmedin Morina, PhD", 
                "phone": "0031-205257084"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "zip": "1018 XA"
                }, 
                "name": "University of Amsterdam, Department of Clinical Psychology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "other_outcome": [
            {
                "description": "Focus of Attention will be assessed during the course of four weeks of exposure therapy that will take place twice a week (session 3 until 9). Change from pre-treatment to post-treatment (5 weeks) as well as change during treatment (four weeks) will be assessed.", 
                "measure": "Change from baseline and in-treatment change: Focus of Attention Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), change during the course of four weeks of exposure therapy (session 3 until 9)"
            }, 
            {
                "description": "The Social Phobia Weekly Summary Scale will be used in each session during the course of the treatment that will take place twice a week (session 1 until 10). Change during treatment will be assessed.", 
                "measure": "In-treatment change: Social Phobia Weekly Summary Scale", 
                "safety_issue": "No", 
                "time_frame": "Change from session to session during the course of five weeks (i.e., session 1 until 10)"
            }, 
            {
                "description": "Change from pre-treatment to sessino 7 (3,5 weeks) and to post-treatment (5 weeks).", 
                "measure": "Change from baseline:Social Cost Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to session 7 (3,5 weeks) and post-treatment (5 weeks)"
            }, 
            {
                "measure": "Experiences in Close Relationships Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment"
            }, 
            {
                "description": "Self-efficacy will be used in each session during the course the treatment that will take place twice a week (session 1 until 10). Change during treatment will be assessed (5 weeks).", 
                "measure": "In treatment change: Self-efficacy for Social Situations", 
                "safety_issue": "No", 
                "time_frame": "Change from session to session during the course of five weeks (i.e., session 1 until 10)"
            }, 
            {
                "description": "Change during treatment (with an expected average of two weeks) will be assessed.", 
                "measure": "In-treatment change: Working Alliance Inventory -Short Revised", 
                "safety_issue": "No", 
                "time_frame": "Session 3 to session 6 (two weeks)"
            }, 
            {
                "description": "This scale will be used in the Virtual Reality condition only", 
                "measure": "Simulator Sickness Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Session 2 (first week of treatment)"
            }, 
            {
                "measure": "Credibility and Expectancy Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Session 3 (second week of treatment)"
            }, 
            {
                "description": "This scale will be used in the Virtual Reality condition only to measure change in the sense of presence from session 2 to session 3 (one week) and session 6 (three weeks).", 
                "measure": "In-treatment change: Ingroup Presence Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Session 2 to session 3 (one week) and session and 6 (three weeks)."
            }, 
            {
                "description": "An implicit measure to assess attentional bias in social phobia. Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Dot-Probe Task", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up."
            }, 
            {
                "description": "A computer task to assess automatic approach and avoidance tendencies by measuring reaction times for pushing away or pulling closer faces with a joystick. Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Approach Avoidance Task", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up."
            }
        ], 
        "overall_contact": {
            "email": "I.L.Kampmann@uva.nl", 
            "last_name": "Isabel L Kampmann, MSc", 
            "phone": "0031-205257084"
        }, 
        "overall_contact_backup": {
            "email": "n.morina@uva.nl", 
            "last_name": "Nexhmedin Morina, PhD", 
            "phone": "0031-2052580607"
        }, 
        "overall_official": [
            {
                "affiliation": "VU University of Amsterdam", 
                "last_name": "Paul GM Emmelkamp, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "VU University of Amsterdam", 
                "last_name": "Nexhmedin Morina, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands:  Independent Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Liebowitz Social Anxiety Scale-Self report", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up."
            }, 
            {
                "description": "Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Fear of Negative Evaluation Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746667"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VU University of Amsterdam", 
            "investigator_full_name": "Paul M.G.Emmelkamp", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The BAT consists of a videotaped 5 minute impromptu speech in front of two confederates. The Public Speaking Performance Scale will be used to evaluate the performance during the speech, both by patients and indipendent raters.\nChange from pre-treatment to post-treatment (5 weeks) will be examined.", 
                "measure": "Change from baseline: Behavioral Assessment Task (BAT), Public Speaking Performance Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks)"
            }, 
            {
                "description": "Change in diagnosis of Social Phobia from pre-treatment to three months follow-up.", 
                "measure": "Change from baseline: Structured Clinical Interview for DSM-IV (Social Phobia Module)", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to three months follow-up."
            }, 
            {
                "description": "Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Depression Anxiety Stress Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up."
            }, 
            {
                "description": "Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Personality Disorder Belief Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up."
            }, 
            {
                "description": "Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.", 
                "measure": "Change from baseline: Eurohis Quality of Life Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up."
            }
        ], 
        "source": "VU University of Amsterdam", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VU University of Amsterdam", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}